Biotyping and susceptibility behaviour of pathogens in patients treated with ciprofloxacin.
Krasemann
C
C
Pharma Research Center, Bayer AG, D-5600 Wuppertal 1, FRG.
Von Poppel
H
H
Wegge
M
M
Chysky
V
V
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002939:Ciprofloxacin / Q000627:therapeutic use*; D018849:Controlled Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy / Q000382:microbiology*; D014552:Urinary Tract Infections / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D002939:Ciprofloxacin